Validation of an ultra-high performance liquid chromatography tandem mass spectrometric method for quantifying uracil and 5,6-dihydrouracil in human plasma

Journal of Chromatographic Science

Volumn 50, Issue 10, 2012, Pages 877-884

  Coudoré, François ^a,c   Roche, Denis ^a   Lefeuvre, Sandrine ^b   Faussot, Delphine ^a   Billaud, Eliane M ^b,d   Loriot, Marie Anne ^a,d   Beaune, Philippe ^a,d  

^a Biochemistry Department   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROURACIL; DRUG DERIVATIVE; URACIL;

ARTICLE; BLOOD; CHEMISTRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; METHODOLOGY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; TANDEM MASS SPECTROMETRY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; LINEAR MODELS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; URACIL;

EID: 84868535362     PISSN: 00219665     EISSN: None     Source Type: Journal    
DOI: 10.1093/chromsci/bms085     Document Type: Article

References (25)

1. Van Kuilenburg, A.B.; Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil; European Journal of Cancer, (2004); 40: 939-950. (Pubitemid 38496249)
2. Di Paolo, A., Danesi, R., Falcone, A., Cionini, L., Vannozzi, F., Masi, G., et al.; Relationship between 56fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients; Annals of Oncology, (2001); 12: 1301-1306. (Pubitemid 32994761)
3. Boisdron-Celle, M., Remaud, G., Traore, S., Poirier, A.L., Gamelin, L., Morel, A., et al.; 5-fluorouracil-related severe toxicity: A comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency; Cancer Letter, (2007); 249: 271-282. (Pubitemid 46452935)
4. Gamelin, E., Boisdron-Celle, M., Morel, A.; Detection of dihydropyrimidine dehydrogenase deficiency before treatment by fluoropyrimidines; Therapie, (2007); 62: 99-103. (Pubitemid 351293213)
5. Sparidans, R.W., Bosch, T.M., Jorger, M., Schellens, J.H.M., Beijnen, J.H.; Liquid chromatography-tandem mass spectrometric assay for the analysis of uracil breakdown in urine for the measurement of the activities and phenotyping of the corresponding pyrimidine catabolic enzymes; Journal of Chromatography B, (2006); 839: 45-53. (Pubitemid 44056041)
6. Gamelin, E., Delva, R., Jacob, J., Merrouche, Y., Raoul, J.L., Pezet, D., et al.; Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage : results of a multicenter randomized trial of patients with metastatic colorectal cancer; Journal of Clinical Oncology, (2008); 26: 2099-2105.
7. Van Kuilenburg, A.B., Klumpen, H.J., Westermann, A.M., Zoetekouw, L., Biker, P.J., Guchelaar, H.J., et al.; Altered dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil containing chemotherapy; Nucleosides, Nucleotides and Nucleic Acids, (2008); 27: 726-732. (Pubitemid 351948585)
8. Van Kuilenburg, A.B., Dobritzsch, D., Meijer, J., Meinsma, R., Benoist, J.F., Assmann, B., et al.; Dihydropyrimidine dehydrogenase deficiency: Phenotype, genotype and structural consequences in 17 patients; Biochimica & Biophysica Acta, (2010); 1802: 639-648.
9. Yukimoto, I., Shigeru, S., Yasuo, T., Tadatoshi, T., Satoshi, A.; Can the 2-13C-uracil breath test be used to predict the effect of the antitumor drug S-1?; Cancer Chemotherapy and Pharmacology, (2010); 66: 333-343.
10. Garg, M.B., Sevester, J.C., Sakoff, J.A., Ackland, S.P.; Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: A potential predictor of 5-fluorouracil toxicity; Journal of Chromatography B, (2002); 774: 223-230. (Pubitemid 34655494)
11. Cicccolini, J., Mercier, C., Blachon, M.F., Favre, R., Durand, A., Lacarelle, B.;A simple and rapid high-performance chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity; Journal of Clinical Pharmacy and Therapeutics, (2004); 29: 307-315. (Pubitemid 39062160)
12. Dé porte, R., Amiand, M., Moreau, A., Charbonnel, C., Campion, L.; High performance liquid chromatographic assay with UV detection for measurement of dihydrouracil/uracil ratio in plasma; Journal of Chromatography B, (2006); 834: 170-177.
13. Van de Merbel, N.C.; Quantitative determination of endogenous compounds in biological samples using chromatographic techniques; Trends in Analytical Chemistry, (2008); 27: 924-33.
14. Remaud, G., Boisdron-Celle, M., Hameline, C., Morel, A., Gamelin, E.; An accurate dihydrouracil/uracil determination using improved high performance liquid chromatography method preventing fluoropyrimidines-related toxicity in clinical practice; Journal of Chromatography B, (2005); 823: 98-107. (Pubitemid 41116751)
15. Svobaite, R., Solassol, I., Pinguet, F., Ivanauskas, L., Bre s, J., Bressolle, F.M.; HPLC with UV or mass spectrometric detection for quantifying endogenous uracil and dihydrouracil in human plasma; Clinical Chemistry, (2008); 54: 1463-1472.
16. Jiang, H., Jiang, J., Hu, P., Hu, Y.; Measurement of endogenous uracil and dihydrouracil in plasma and urine of normal subjects by liquid chromatography-tandem mass spectrometry; Journal of Chromatography B, (2002); 769: 169-176. (Pubitemid 34188391)
17. USFDA; Guidance for Industry, Bioanalytical Method Validation. (2001) http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/ Guidances/ucm070107.pdf (accessed January 19, 2012).
18. Bonfiglio, R., King, R.C., Olah, T.V., Merkle, K.; The effect of sample preparation methods on the variability of the electrospray ionization response for model drug compounds; Rapid Communications in Mass Spectrometry, (1999); 13: 1175-1185 (Pubitemid 29285118)
19. Matuszewski, B.K.; Standard line slopes as a measure of a relative matrix effect in quantitative HPLC-MS bioanalysis; Journal of Chromatography B, (2006); 830: 293-300. (Pubitemid 43075465)
20. Nakayama, Y., Matsumoto, K., Inoue, Y., Katsuki, T., Kadowaki, K., Shibao, K., et al.; Correlation between the urinary dihydrouracil/ uracil ratio and the 5-FU plasma concentration in patients treated with oral 5-FU analogs; Anticancer Research, (2006); 26: 3983-3988. (Pubitemid 44701486)
21. van Kuilenburg, A., van Lenthe, H., van Cruchten, A., Kulik, W.; Quantification of 5,6-dihydrouracil by HPLC-electrospray tandem mass spectrometry; Clinical Chemistry, (2004); 50: 236-238. (Pubitemid 38125733)
22. Morel, A., Boisdron-Celle, M., Fey, L., Laine-Cessac, P., Gamelin, E.; Identification of a novel mutation in dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma; Clinical Biochemistry, (2007); 40: 11-17. (Pubitemid 46014150)
23. Ciccolini, J., Mercier, C., Evrard, A., Boyer, J., Duffaud, F., Dahan, L., et al.; A rapid and inexpensive method for anticipating severe toxicity to 5-FU based chemotherapy; Therapeutic Drug Monitoring, (2006); 28: 678-685. (Pubitemid 44564069)
24. Chambers, E., Wagrowski-Diehl, D.M., Lu, Z., Mazzeo, J.R.; Systematic and comprehensive strategy for reducing matrix effects in LC/MS/MS analysis; Journal of Chromatography B, (2007); 852: 22-34. (Pubitemid 46830084)
25. Jiang, H., Lu, L., Ji, J.; Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels; British Journal of Pharmacology, (2004); 141: 616-623. (Pubitemid 38453253)